{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-037818","form_type":"8-K","ticker":"PIII","cik":"0001832511","company_name":"P3 Health Partners Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.865710+00:00","generated_at":"2026-06-08T10:39:24.008097+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"P3 Health Partners Q3 revenue $288.4M (+16% YoY); net loss narrows; guides for positive 2024 Adj EBITDA","bullets":["Q3 total revenue $288.4M, up 16% YoY; net loss $37.3M vs. $65.3M loss prior year.","Adjusted EBITDA loss $22.3M, improved from $40.3M loss YoY; medical margin $36.2M, +306%.","YTD total revenue $919.5M (+16%); net loss $117.3M vs. $1,029.2M loss (incl. $851M goodwill impairment).","Reaffirms FY 2023 guidance: revenue $1.2B-$1.25B, Adj EBITDA loss $(50)-$(30)M; MA members 115k-120k.","Preliminary FY 2024 Adj EBITDA guidance of +$20M to +$40M, signaling expected profitability."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-037818","json":"https://secwatch.observer/filing/0001628280-23-037818.json","markdown":"https://secwatch.observer/filing/0001628280-23-037818.md","text":"https://secwatch.observer/filing/0001628280-23-037818.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832511/000162828023037818/0001628280-23-037818-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832511/000162828023037818/piii-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T10:39:24.008097+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8fdb73db36c95b1a87c693124f7f2365e49e72a6","claim":"P3 Health Partners Inc. reported three and nine months ended September 30, 2023 results: revenue $288.4 million, net income Net loss was $37.3 million. Guidance reaffirmed.","evidence_excerpt":"preliminary 2024 full-year Adjusted EBITDA guidance of $20 million to $40 million,” said Dr. Sherif Abdou, CEO of P3. Third-Quarter 2023 Financial Results • Total revenue was $288.4 million, an increase of 16% compared to $248.3 million in the third quarter of the prior year. Net loss was $37.3 million, an increase of approximately 43% compared to a net loss of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1832511/000162828023037818/0001628280-23-037818-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2023"},{"label":"Revenue","value":"$288.4 million"},{"label":"Net income","value":"Net loss was $37.3 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}